刘利平博士为君圣泰创始人及首席执行官，于1994年获得南开大学高分子化学与物理博士学位，之后赴加拿大多伦多大学从事博士后研究。2009年刘博士获得了美国约翰霍普金斯大学凯瑞商学院授予的MBA学位。从事新药开发27年，领导并参与新药开发项目近10个，拥有在美国成功完成新药开发并批准上市的经验。在国际刊物发表论文20多篇，已获得近40项国际专利授权。

刘利平博士2011年回国，创办了君圣泰至今，主要从事新药开发。君圣泰是一家立足中国，具有国际竞争力的原创新药研发公司，聚焦未满足的临床需求。公司所开发的药物拥有全球自主知识产权，专注于慢性肝病、消化系统和代谢疾病领域。 目前已完成多项临床2期试验，试验结果在国际刊物发表，并在国际学术会议做大会报告。

公司获得2项中国“十三五新药创制重大专项”，并被FDA（美国食品药品监督管理局）授予2项FTD（快速审评通道资格认定）、1项ODD（孤儿药资格认定）。

刘博士在行业及商界获得多项殊荣，其中分别包括知名行业及商业媒体评选的“Biotech 15人”、“2021年值得关注的女性创业领袖”、“十大创新科学家”等。

Dr. Liping Liu is the founder and CEO of High Tide. She received her Ph.D. degree from Nankai University in 1994 and completed a postdoctoral fellowship training in  University of Toronto and Hospital for Sick Children in Canada.  Dr. Liu received her MBA degree from Carey Business School at Johns Hopkins University in 2009.  She has been engaged in new drug development for 27 years, led and participated in nearly 10 new drug development projects, and has the experience of successfully completing new drug development and marketing approval in the United States.  She has published more than 20 papers in international journals and obtained nearly 40 international patents.

Dr. Liu returned to China in 2011 and founded High Tide Therapeutics Inc.  Headquartered in China, High Tide is a global clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutics for non-viral chronic liver diseases, gastrointestinal diseases and metabolic disorders, with a focus on unmet medical needs. High Tide has completed several phase 2 clinical trials with results published in peer reviewed journals and presented at the international meetings.